Embody is pioneering the next generation regenerative platform for the repair of tendon and ligament injuries with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market. Founded in 2014 and funded with $20 million in DARPA & DOD funding, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair, including ACL (Anterior Cruciate Ligament).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/05/20 | $9,300,000 | Series A |
757 Angels cultivate(MD) Capital Funds Litigit  | undisclosed |
| 09/20/22 | $10,400,000 | Series C |
cultivate(MD) Capital Funds | undisclosed |
